Background The synergy between locoregional therapies and immune checkpoint inhibitors
has not been investigated as conversion therapy for unresectable hepatocellular carcinoma …

Hepatocellular Carcinoma (HCC) is one of the most common cancers and a leading cause
of cancer related death worldwide. Until recently, systemic therapy for advanced HCC …

The liver tumor immune microenvironment has been thought to possess a critical role in the
development and progression of hepatocellular carcinoma (HCC). Despite the approval of …

Introduction: While combination of stereotactic body radiotherapy (SBRT) and
immunotherapy are promising, their efficacy and safety have not been compared with SBRT …

Simple Summary Hepatocellular carcinoma (HCC) is one of the most prevalent and
devastating malignancies worldwide. An ongoing phase-II clinical trial assesses the efficacy …

Advanced hepatocellular carcinoma (HCC) is traditionally associated with limited treatment
options and a poor prognosis. Sorafenib, a multiple tyrosine kinase inhibitor, was introduced …

Purpose. This study aimed to investigatie the feasibility of pretherapeutic CT radiomics‐
based nomograms to predict the overall survival (OS) of patients with nondistant metastatic …

The liver is a functionally unique organ with an immunosuppressive microenvironment. The
liver is the sixth most common site of primary cancer in humans and is a frequent site of …

Purpose In this study, we aimed to compare the radiation-induced hepatic toxicity (RIHT)
outcomes of radiotherapy (RT) plus antibodies against programmed cell death protein 1 …

Hepatocellular carcinoma (HCC) is a common malignancy with high mortality rates. While
surgery can be curative in early-stage disease, 80% of patients cannot undergo surgical …